177 related articles for article (PubMed ID: 21933446)
1. Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B.
Yeh CT; Chen T; Hsu CW; Chen YC; Lai MW; Liang KH; Chen TC
BMC Cancer; 2011 Sep; 11():398. PubMed ID: 21933446
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation.
Zhao L; Li X; Cheng Y; Chen R; Shao J; Zhou Y; Li Q; Liao H; Zhao Y; Liu L; Su H; Liu Y; Liu Y; Xu D
Antiviral Res; 2018 Jun; 154():26-34. PubMed ID: 29630974
[TBL] [Abstract][Full Text] [Related]
3. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.
Chen CH; Wang JH; Lu SN; Hu TH; Hung CH; Chang MH; Changchien CS; Lee CM
Antivir Ther; 2012; 17(4):701-9. PubMed ID: 22358132
[TBL] [Abstract][Full Text] [Related]
4. Nucleos(t)ide analogues causes HBV S gene mutations and carcinogenesis.
Wang ML; Tang H
Hepatobiliary Pancreat Dis Int; 2016 Dec; 15(6):579-586. PubMed ID: 27919846
[TBL] [Abstract][Full Text] [Related]
5. Antiviral efficacy of entecavir for hepatitis B virus rtA181V/T mutants.
Li P; Geng J; Li W; Xu X; Zhang X; Zheng W; Yu Y; Yang Z; Wang M
Virol J; 2017 Apr; 14(1):68. PubMed ID: 28376852
[TBL] [Abstract][Full Text] [Related]
6. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.
Yatsuji H; Suzuki F; Sezaki H; Akuta N; Suzuki Y; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Watahiki S; Iwasaki S; Kobayashi M; Kumada H
J Hepatol; 2008 Jun; 48(6):923-31. PubMed ID: 18433925
[TBL] [Abstract][Full Text] [Related]
7. The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant.
Lai MW; Yeh CT
Antivir Ther; 2008; 13(7):875-9. PubMed ID: 19043921
[TBL] [Abstract][Full Text] [Related]
8. Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection.
Kurokawa M; Hiramatsu N; Oze T; Yakushijin T; Miyazaki M; Hosui A; Miyagi T; Yoshida Y; Ishida H; Tatsumi T; Kiso S; Kanto T; Kasahara A; Iio S; Doi Y; Yamada A; Oshita M; Kaneko A; Mochizuki K; Hagiwara H; Mita E; Ito T; Inui Y; Katayama K; Yoshihara H; Imai Y; Hayashi E; Hayashi N; Takehara T
J Gastroenterol; 2012 May; 47(5):577-85. PubMed ID: 22231575
[TBL] [Abstract][Full Text] [Related]
9. Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment.
Margeridon-Thermet S; Svarovskaia ES; Babrzadeh F; Martin R; Liu TF; Pacold M; Reuman EC; Holmes SP; Borroto-Esoda K; Shafer RW
Antimicrob Agents Chemother; 2013 Jan; 57(1):343-9. PubMed ID: 23114756
[TBL] [Abstract][Full Text] [Related]
10. Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma.
Shin HS; Kim SU; Park JY; Kim DY; Han KH; Chon CY; Baatarkhuu O; Ahn SH
J Gastroenterol Hepatol; 2012 Sep; 27(9):1528-34. PubMed ID: 22497450
[TBL] [Abstract][Full Text] [Related]
11. [Clinical emergence features and implications of hepatitis B virus rtA181T mutation].
Li X; Jiang L; Li F; Liu Y; Dai J; Zhao P; Qin Y; Li J; Xu D
Zhonghua Gan Zang Bing Za Zhi; 2015 Jan; 23(1):23-7. PubMed ID: 25751382
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance.
Elefsiniotis I; Buti M; Jardi R; Vezali E; Esteban R
Eur J Intern Med; 2009 Sep; 20(5):478-81. PubMed ID: 19712848
[TBL] [Abstract][Full Text] [Related]
13. [Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients].
Cho JH; Cheong JY; Kang JK; Park JS; Lee MH; Lim NK; Hong SP; Kim SO; Yoo WD; Cho SW
Korean J Hepatol; 2008 Mar; 14(1):58-66. PubMed ID: 18367858
[TBL] [Abstract][Full Text] [Related]
14. Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
Li X; Liu Y; Zhao P; Wang Y; Chen L; Xin S; Zhang XX; Xu D
Antivir Ther; 2015; 20(2):141-7. PubMed ID: 24992206
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
[TBL] [Abstract][Full Text] [Related]
16. The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene.
Ahn SH; Park YK; Park ES; Kim JH; Kim DH; Lim KH; Jang MS; Choe WH; Ko SY; Sung IK; Kwon SY; Kim KH
J Virol; 2014 Jun; 88(12):6805-18. PubMed ID: 24696492
[TBL] [Abstract][Full Text] [Related]
17. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma.
Yang HI; Yeh SH; Chen PJ; Iloeje UH; Jen CL; Su J; Wang LY; Lu SN; You SL; Chen DS; Liaw YF; Chen CJ;
J Natl Cancer Inst; 2008 Aug; 100(16):1134-43. PubMed ID: 18695135
[TBL] [Abstract][Full Text] [Related]
18. Core promoter mutant HBV non-responding to adefovir after viral breakthrough on lamivudine: rapid virologic response to tenofovir plus lamivudine in a cirrhotic patient.
Katsounas A; Jochum C; Canbay A; Schlaak J; Gerlich WH; Gerken G
Eur J Med Res; 2008 Oct; 13(10):472-5. PubMed ID: 19008175
[TBL] [Abstract][Full Text] [Related]
19. Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
Intervirology; 2008; 51(6):385-93. PubMed ID: 19229115
[TBL] [Abstract][Full Text] [Related]
20. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B.
Cha CK; Kwon HC; Cheong JY; Cho SW; Hong SP; Kim SO; Yoo WD
J Med Virol; 2009 Mar; 81(3):417-24. PubMed ID: 19152409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]